TrialsgrambetaRCTs are beautiful

EAGLES

2016

Evaluating Adverse Events in a Global Smoking Cessation Study

In 8,144 smokers with and without psychiatric disorders, varenicline produced higher continuous abstinence at weeks 9–12 than bupropion, nicotine patch or placebo, without excess neuropsychiatric events.

Result

Primary endpoint: Continuous abstinence weeks 9–12; neuropsychiatric adverse events

Abstinence varenicline 33.5%, bupropion 22.6%, NRT 23.4%, placebo 12.5%. No excess NPS adverse events.

Original publication
Subtopic
Varenicline / bupropion / NRT
Design
Multicentre 4-arm RCT
Relevance
Important: one of several pillars.
Source
Anthenelli RM, et al. Lancet. 2016;387(10037):2507-2520.doi 10.1016/S0140-6736(16)30272-0

Discussion & critique

FDA removed the neuropsychiatric black-box warning for varenicline; remains the most effective monotherapy for tobacco dependence.

Discussed in podcasts